Drug Trial Radar · NCT01339312
Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine
Last checked: Nov 19, 2026Latest source record: May 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
816
Actual
Start
Apr 2011
Primary completion
Mar 2012
Study completion Sep 2012
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Apr 20, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is designed to gather safety and immunogenicity data with Purified Vero Rabies Vaccine - Serum Free (VRVg), when given in a post-exposure prophylaxis vaccination schedule, using the Essen regimen, across different populations. Primary Objective: * To demonstrate that VRVg is at least as immunogenic as the reference vaccine, Verorab vaccine, in terms of proportion of participants with a rabies virus neutralizing antibody titer ≥ 0.5 IU/mL at Day 14, i.e., before the fourth vaccination, in participants aged 10 to 17 years and in participants aged 18 years and over. Secondary Objectives: * To assess the clinical safety of VRVg after each vaccination when administered in a post-exposure prophylaxis vaccination schedule in each respective age group and overall * To describe the immune response induced by VRVg before the fourth vaccination and 14 days after the last vaccination in each respective age groups and overall.
Conditions
- Rabies
- Rabies Virus
Interventions
Purified inactivated rabies vaccine, serum freeBiological
0.5 mL, Intramuscular
Purified inactivated rabies vaccine, serum freeBiological
0.5 mL, Intramuscular
Purified Vero Rabies VaccineBiological
0.5 mL, Intramuscular
Purified Vero Rabies VaccineBiological
0.5 mL, Intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Information on the rabies virus neutralizing antibody (RVNA) titer post vaccinationTime frame: Day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Nanning, Guangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.